| Oral, Elif A |
NCT04026178: Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy |
|
|
| Active, not recruiting | 4 | 10 | US | Metreleptin | Aegerion Pharmaceuticals, Inc. | Generalized Lipodystrophy | 10/24 | 04/25 | | |
| Recruiting | 3 | 15 | US | Metreleptin | Amryt Pharma | Familial Partial Lipodystrophy | 03/28 | 03/28 | | |
METRE-PL, NCT05164341: Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL |
|
|
| Recruiting | 3 | 65 | Europe, Canada, US, RoW | metreleptin, Placebo | Amryt Pharma | Partial Lipodystrophy | 06/25 | 01/26 | | |
NCT05351164: Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL) |
|
|
| Active, not recruiting | 2 | 4 | US | Metreleptin | University of Michigan, Amryt Pharma | Lipomatosis, Multiple Symmetrical | 04/24 | 04/25 | | |
LEAP, NCT05088460 / 2021-000138-33: A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) |
|
|
| Terminated | 2 | 20 | Europe, US, RoW | REGN4461, mibavademab, Matching Placebo | Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc. | Familial Partial Lipodystrophy, Metabolic Abnormalities | 12/23 | 04/24 | | |
| Available | N/A | | US | Metreleptin, MyaLept | University of Michigan | Familial Partial Lipodystrophy | | | | |
| Recruiting | N/A | 264 | US | RESET Liner, RESET Sleeve, Duodenal-jejunal Bypass Liner (DJBL), EndoBarrier, Sham | Morphic Medical Inc., Biostatistical Consulting, Inc. | Diabetes type2, Obesity | 12/25 | 12/26 | | |
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes |
|
|
| Suspended | N/A | 320 | Europe, US | Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham) | Fractyl Health Inc. | Type 2 Diabetes | 06/25 | 01/26 | | |
NCT03087253: The LD Lync Study - Natural History Study of Lipodystrophy Syndromes |
|
|
| Recruiting | N/A | 500 | US, RoW | | University of Michigan | Lipodystrophy (Genetic or Acquired, Non HIV) | 03/31 | 03/31 | | |
| Recruiting | N/A | 100 | Europe, US | Metreleptin | Aegerion Pharmaceuticals, Inc. | Generalised Lipodystrophy, Partial Lipodystrophy | 10/31 | 10/31 | | |
| Recruiting | N/A | 2000 | US | | University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases | 09/30 | 09/30 | | |
| Fornoni, Alessia |
| Recruiting | N/A | 1200 | Canada, US | Kidney Biopsy | University of Michigan, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The NephCure Foundation | Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental | 06/26 | 06/26 | | |
| Recruiting | N/A | 5000 | US | | Wake Forest University Health Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Allergy and Infectious Diseases (NIAID) | Kidney Diseases, Kidney Failure, Kidney Disease, Chronic | 09/24 | 09/24 | | |
| Czerr, Jennifer |
| Active, not recruiting | 2 | 20 | Europe, US | Vonafexor, EYP001a | Enyo Pharma | Alport Syndrome | 07/25 | 10/25 | | |
| Recruiting | N/A | 5000 | US | | Wake Forest University Health Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Allergy and Infectious Diseases (NIAID) | Kidney Diseases, Kidney Failure, Kidney Disease, Chronic | 09/24 | 09/24 | | |
| Neidert, Adam H |
| Available | N/A | | US | Metreleptin, MyaLept | University of Michigan | Familial Partial Lipodystrophy | | | | |
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes |
|
|
| Suspended | N/A | 320 | Europe, US | Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham) | Fractyl Health Inc. | Type 2 Diabetes | 06/25 | 01/26 | | |
NCT03087253: The LD Lync Study - Natural History Study of Lipodystrophy Syndromes |
|
|
| Recruiting | N/A | 500 | US, RoW | | University of Michigan | Lipodystrophy (Genetic or Acquired, Non HIV) | 03/31 | 03/31 | | |
| Recruiting | N/A | 2000 | US | | University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases | 09/30 | 09/30 | | |
| Doshi, Mona D |
| Recruiting | 2/3 | 180 | US | Anti-BK polyomavirus (AntiBKV) | Memo Therapeutics AG | BK Viremia; BKV DNAemia | 11/24 | 11/24 | | |
| Recruiting | N/A | 5000 | US | | Wake Forest University Health Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Allergy and Infectious Diseases (NIAID) | Kidney Diseases, Kidney Failure, Kidney Disease, Chronic | 09/24 | 09/24 | | |
